Thrombocytopenia and guideline‐evaluated appropriateness of platelet transfusion in a tertiary care intensive care unit
ConclusionThrombocytopenia is common in ICU patients, and a significant proportion of ICU patients receive platelet transfusions to control bleeding and maintain haemostasis. A minority of patients receive inappropriate platelet transfusions with unclear benefits with a potential to develop serious transfusion‐related adverse events. (Source: ISBT Science Series)
Source: ISBT Science Series - July 18, 2016 Category: Hematology Authors: B.K. Vasu, R. Sinha, S. Verghese Tags: Original Paper Source Type: research
Transfusion risk from emerging pathogens in the Asia –Pacific region
BackgroundAn emerging infectious disease (EID) refers to a disease that has recently appeared in a population or one that has rapidly increased in incidence or geographic range. Examples of EIDs include Ebola, HIV/AIDS, hepatitis E and the vector‐borne diseases caused by Zika and dengue virus. EIDs pose a risk to transfusion safety, which can be direct, if the agent can be transmitted through blood transfusion, or indirect, where outbreaks reduce the pool of available donors. Although examples of both have been observed, the former will be the focus of this review. Many transfusion risks have become global due to globali...
Source: ISBT Science Series - June 27, 2016 Category: Hematology Authors: H. M. Faddy, E. Viennet, R. L. P. Flower Tags: Invited Review Source Type: research
The current status of nucleic acid amplification technology in transfusion ‐transmitted infectious disease testing
Fully automated multiplex nucleic acid amplification technology (NAT) enabling individual‐donation (ID) or minipool of 6 (MP6) screening for HIV, HCV and HBV is provided by two major commercial players (Grifols/Hologic and Roche). In August 2014, Roche released the cobas MPX assay performed on the high‐throughput cobas 8800 and 6800 instruments. Grifols recently released their Ultrio Elite assay which includes detection of HIV‐2 and is performed on the Panther platform and allows random access of sample and reagent loading during processing, which streamlines functionality and improves turnaround time. At the end of ...
Source: ISBT Science Series - June 27, 2016 Category: Hematology Authors: M. Vermeulen, N. Lelie Tags: Special Issue Source Type: research
Assessing the risk of transfusion ‐transmitted emerging infectious diseases
BackgroundEmerging infectious diseases (EIDs) remain a source of significant concern in blood safety.
MethodsEmerging infectious diseases of concern will be described and methods used to conduct risk assessment will be reviewed, with a focus on transfusion medicine. The issues that make EIDs more challenging for blood safety compared to other areas of public health will be demonstrated through specific examples.
ResultsCurrent EIDs include mosquito‐borne infections such as dengue, chikungunya and Zika virus. In addition, tick‐borne infections such as Babesia, Borrelia, Anaplasma and Severe Fever with Thrombocytopenia S...
Source: ISBT Science Series - June 27, 2016 Category: Hematology Authors: B. Custer Tags: Invited Review Source Type: research
CD36 deficiency among South ‐East Asian populations
Immune‐mediated thrombocytopenia is commonly caused by platelet‐reactive antibodies mostly against polymorphic structures residing on platelet glycoproteins such as human leucocyte antigen and human platelet antigen (HLA class I and HPA). In the Japanese population, some individuals do not express CD36 (CD36null also known as Naka) on the cell surface. Immunization of these individuals can lead to the development of CD36 isoantibodies (anti‐Naka) which play a role in the mechanism of platelet transfusion refractoriness, post‐transfusion purpura and fetal/neonatal alloimmune thrombocytopenia. Until today, however, l...
Source: ISBT Science Series - June 27, 2016 Category: Hematology Authors: W. Xia, X. Xu, Y. Fu, X. Ye, N. Tsuno, S. Santoso, Tags: Special Issue Source Type: research
